Jul 2026· ACS Bio & Med Chem Au· Vol 6, pp. 323 - 328· 0 citations· 27 references
Medicine
Abstract
The variable domains of heavy chain only antibodies, also called nanobodies, have provided powerful new tools for biomedical research. Their rapid development across multiple fields has helped address emerging scientific and clinical challenges, establishing single-domain antibodies (sdAbs) as highly adaptable platforms for a wide range of biotechnological and therapeutic applications. In this study, we identified a nanobody from an alpaca immune library, sdAbCM1, that binds to the maltose-maltodextrin binding protein, MBP, with picomolar affinity. Biophysical investigations showed that sdAbCM1 recognizes a yet unreported epitope and interacts with MBP in its closed conformation when maltose is present. The high affinity, epitope specificity, and ability to tolerate the ligand-bound state render sdAbCM1 a valuable and versatile biotechnological tool with potential applications such as detection, localization, and purification of MBP fusion proteins and protein complex engineering for single-particle microscopy.
Nanobodies are a class of small, monomeric camelid antibody fragments that can bind target antigens with high affinity and specificity. Their small size, structural simplicity, and limited reliance on disulfide bonding makes them attractive for intracellular expression for labeling and perturbing cellular processes in...
J. Wang, Victor L. Lam, E. Dunn et al.· bioRxiv· 0 citations
Nanobodies (Nbs) have been extensively utilized in medical diagnosis and therapies due to their advantages, such as ease of genetic manipulation and efficient soluble expression in prokaryotic systems. However, enhancing their binding affinity to antigens to match or even exceed that of polyclonal antibodies for high-s...
Hong-Heng Li, Chen-Chen Zhou, Xiao-Mei Zhang et al.· Experimental and Therapeutic...· 0 citations
A protocol for discovering protein‐binding peptides using a very large, target‐agnostic yeast surface display library containing approximately 6.1 × 109 unique clones and providing broad coverage of short peptide sequence space is described.
J. D. Hurley, Andrew C. Kruse· Current Protocols· 0 citations
Monoclonal antibodies (mAbs) are widely used as therapeutic molecules for the treatment of serious diseases, primarily cancer. The market for mAbs is one of the fastest-growing segments of the biopharmaceuticals industry. Purification is a crucial stage in the production of mAbs. While staphylococcal protein A (SpA) af...
L. N. Ikryannikova, M. N. Tereshin, Milena V. Baskova et al.· International Journal of Mol...· 0 citations
Nanobodies have recently emerged as an alternative to classical antibodies in therapeutic and diagnostic contexts, promising improved stability and simpler manufacturing. However, many labs still rely on low throughput conventional screening methods for nanobody discovery. Here we report streamlined experimental...
William L. White, Edward H. Moseley, Jacqueline M. Tremblay et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
